Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,318 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Control of Regulatory T Cell Development by the Transcription Factor <i>Foxp3</i>

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · see citing works

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · see citing works

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Regulatory T Cells and Immune Tolerance

Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,336 · see citing works

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis

Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3

Chen, W., Jin, W., Hardegen, N. J., Lei, K.-J., Li, L., Marinos, N. J., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,678 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

TGFβ in Cancer

Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · see citing works

TGFβ in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T Cells

Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · see citing works

TGFβ signalling in context

Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,130 · see citing works

Transforming growth factor-β induces development of the TH17 lineage

Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

Immune Checkpoint Blockade in Cancer Therapy

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES

Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,199 · see citing works

Regulatory T cells, tumour immunity and immunotherapy

Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,075 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · see citing works

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754 · see citing works

Plasticity of CD4+ T Cell Lineage Differentiation

Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551 · see citing works

TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355 · see citing works

The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt

Manel, N., Unutmaz, D., & Littman, D. R. (2008) · Nature Immunology · doi:10.1038/ni.1610 · Cited by 1,328 · see citing works

Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327 · see citing works

Cancer despite immunosurveillance: immunoselection and immunosubversion

Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · see citing works

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,285 · see citing works

Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer

Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146 · see citing works

Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3 . Science 2003. 299: 1057–1061

Hori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,067 · see citing works

Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?

de Lafaille, M. A. C., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055 · see citing works

Mechanisms of suppression by suppressor T cells

von Boehmer, H. (2005) · Nature Immunology · doi:10.1038/ni1180 · Cited by 1,005 · see citing works

TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

Marie, J. C., Letterio, J. J., Gavin, M. A., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 986 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice

Ishikawa, F., Yasukawa, M., Lyons, B. L., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 933 · see citing works

The roles of TGFβ in the tumour microenvironment

Pickup, M. W., Novitskiy, S. V., & Moses, H. L. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3603 · Cited by 915 · see citing works

TGF-β: A Master of All T Cell Trades

Li, M. O., & Flavell, R. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.025 · Cited by 888 · see citing works

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 839 · see citing works

Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells

Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835 · see citing works

Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer

Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M. L., Greene, M. I., & Tone, M. (2008) · Nature Immunology · doi:10.1038/ni1549 · Cited by 807 · see citing works

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals <i>in vivo</i>

Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806 · see citing works

Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms

Li, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 794 · see citing works

Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770 · see citing works

Tumor Immunotherapy Directed at PD-1

Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 680 · see citing works

Immunostimulatory monoclonal antibodies for cancer therapy

Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 626 · see citing works

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 620 · see citing works

Control of Regulatory T Cell Lineage Commitment and Maintenance

Josefowicz, S. Z., & Rudensky, A. Y. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.009 · Cited by 570 · see citing works

Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β

Liu, V. C., Wong, L. Y., Jang, T. L., Shah, A. H., Park, I. I., Yang, X. J., Zhang, Q., Lonning, S. M., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453 · see citing works

Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function

Tang, Q., Boden, E. K., Henriksen, K., Bour‐Jordan, H., Bi, M., & Bluestone, J. A. (2004) · European Journal of Immunology · doi:10.1002/eji.200425143 · Cited by 377 · see citing works

Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells

Wu, C., Thalhamer, T., França, R. F. D. O., Xiao, S., Wang, C., Hotta, C., Zhu, C. Y., Hirashima, M., Anderson, A. C., & Kuchroo, V. K. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.011 · Cited by 349 · see citing works

Tumor microenvironments direct the recruitment and expansion of human Th17 cells

Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324 · see citing works

Regulatory T cells and treatment of cancer

Curiel, T. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.008 · Cited by 263 · see citing works

Regulatory T cells in immune surveillance and treatment of cancer

Yamaguchi, T., & Sakaguchi, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.005 · Cited by 263 · see citing works

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · see citing works

Autocrine Transforming Growth Factor-β1 Promotes In Vivo Th17 Cell Differentiation

Gutcher, I., Donkor, M. K., Ma, Q., Rudensky, A. Y., Flavell, R. A., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.005 · Cited by 243 · see citing works

Merging two gene-expression studies via cross-platform normalization

Shabalin, A. A., Tjelmeland, H., Fan, C., Perou, C. M., & Nobel, A. B. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn083 · Cited by 223 · see citing works

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma

Noonan, K. A., Marchionni, L., Anderson, J., Pardoll, D. M., Roodman, G. D., & Borrello, I. (2010) · Blood · doi:10.1182/blood-2010-05-283895 · Cited by 210 · see citing works

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development

Ozerov, I. V., Lezhnina, K. V., Izumchenko, E., Artemov, A. V., Medintsev, S., Vanhaelen, Q., Aliper, A. M., Vijg, J., Osipov, A. N., Labat, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms13427 · Cited by 137 · see citing works

TGF-β-Mediated Suppression by CD4+CD25+ T Cells Is Facilitated by CTLA-4 Signaling

Oida, T., Xu, L., Weiner, H. L., Kitani, A., & Strober, W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2331 · Cited by 131 · see citing works

Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors

Noonan, K. A., Matsui, W. H., Serafini, P., Carbley, R., Tan, G. G. Y., Khalili, J. S., Bonyhadi, M. L., Levitsky, H. I., Whartenby, K., & Borrello, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3337 · Cited by 126 · see citing works

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

Noonan, K. A., Huff, C. A., Davis, J. M., Lemas, M. V., Fiorino, S., Bitzan, J., Ferguson, A. K., Emerling, A., Luznik, L., Matsui, W. H., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7014 · Cited by 125 · see citing works

Regulatory T Cells, Transforming Growth Factor–β, and Immune Suppression

Wan, Y. Y., & Flavell, R. A. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-020aw · Cited by 90 · see citing works

Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity

Liu, Z., Kim, J. H., Falo, L. D., & You, Z. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802664 · Cited by 83 · see citing works

In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia

Makarev, E., Schubert, A. D., Kanherkar, R. R., London, N. R., Teka, M., Ozerov, I. V., Lezhnina, K. V., Bedi, A., Ravi, R. K., Mehra, R., et al. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.22 · Cited by 41 · see citing works

The Therapeutic Implications of Intratumoral Regulatory T Cells

Dranoff, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2035 · Cited by 40 · see citing works

Inhibition of TGF-β1 Signaling Promotes Central Memory T Cell Differentiation

Takai, S., Schlom, J., Tucker, J., Tsang, K. Y., & Greiner, J. W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300472 · Cited by 33 · see citing works

Onco-Hu™ Models: Humanized NSG™ and NSG™-SGM3 Mice for Immuno-Oncology

Clinical, & Mice, J. (2016) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 2 · see citing works

Transforming Growth Factor-β Signaling in Immunity and Cancer

Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366 · see citing works

Crosstalk between cancer‐associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290 · see citing works

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,326 · see citing works

Exploring the NK cell platform for cancer immunotherapy

Myers, J. A., & Miller, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,293 · see citing works

TGF-β signaling in health, disease and therapeutics

Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,306 · see citing works

Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures

Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764 · see citing works

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works

The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 523 · see citing works

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors

Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 418 · see citing works

Targeting TGFβ signal transduction for cancer therapy

Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413 · see citing works

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377 · see citing works

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor

Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365 · see citing works

FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets

Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 357 · see citing works

Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies

Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256 · see citing works

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 265 · see citing works

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · see citing works

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

Li, S., Liu, M., Do, M. H., Chou, C., Stamatiades, E. G., Nixon, B. G., Shi, W., Zhang, X., Li, P., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2850-3 · Cited by 242 · see citing works

Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment

Gao, S., Yang, X., Xu, J., Qiu, N., & Zhai, G. (2021) · ACS Nano · doi:10.1021/acsnano.1c02103 · Cited by 240 · see citing works

Treg-mediated acquired resistance to immune checkpoint inhibitors

Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 238 · see citing works

Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy

Zhang, X., Shi, M., Chen, T., & Zhang, B. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.08.030 · Cited by 231 · see citing works

TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking

Gunderson, A. J., Yamazaki, T., McCarty, K., Fox, N., Phillips, M., Alice, A. F., Blair, T. C., Whiteford, M. H., O’Brien, D. P., Ahmad, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15404-8 · Cited by 223 · see citing works

Chemistry42: An AI-Driven Platform for Molecular Design and Optimization

Ivanenkov, Y. A., Polykovskiy, D., Bezrukov, D., Zagribelnyy, B., Aladinskiy, V., Kamya, P., Aliper, A., Ren, F., & Zhavoronkov, A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01191 · Cited by 231 · see citing works

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works

TGF-beta: a master immune regulator

Larson, C., Oronsky, B. T., Carter, C. A., Oronsky, A. L., Knox, S. J., Sher, D. J., & Reid, T. R. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1744568 · Cited by 220 · see citing works

On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Teixeira, A. F., ten Dijke, P., & Zhu, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 210 · see citing works

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 211 · see citing works

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Paz-Ares, L. G., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Flor, M. J., Nicola, M. D., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 208 · see citing works

Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy

Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., Wang, X., Ke, L., & Shi, K. (2018) · Theranostics · doi:10.7150/thno.29431 · Cited by 199 · see citing works

Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion

Lan, Y., Moustafa, M., Knoll, M., Xu, C., Furkel, J., Lazorchak, A. S., Yeung, T.-L., Hasheminasab, S.-M., Jenkins, M. H., Meister, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.008 · Cited by 200 · see citing works

TGF-β Signaling and Resistance to Cancer Therapy

Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 199 · see citing works

TGF-β suppresses type 2 immunity to cancer

Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2836-1 · Cited by 189 · see citing works

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 182 · see citing works

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174 · see citing works

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

Runcie, K. D., Budman, D. R., John, V. S., & Seetharamu, N. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0051-4 · Cited by 161 · see citing works

PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery

Kamya, P. R. N., Ozerov, I. V., Pun, F. W., Tretina, K., Fokina, T., Chen, S., Naumov, V., Long, X., Lin, S., Korzinkin, M., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01619 · Cited by 156 · see citing works

&lt;p&gt;Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor&lt;/p&gt;

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Strauss, J., Gatti-Mays, M. E., Cho, B. C., Hill, A., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Jochéms, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001395 · Cited by 153 · see citing works

Impairment of NKG2D-Mediated Tumor Immunity by TGF-β

Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149 · see citing works

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 151 · see citing works

Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity

Xue, V. W., Chung, J. Y., Córdoba, C. A. G., Cheung, A. H. K., Kang, W., Lam, E. W. ‐., Leung, K. T., To, K., Lan, H. Y., & Tang, P. M. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 149 · see citing works

The gut microbiome: what the oncologist ought to know

Lee, K. A., Luong, M., Shaw, H. M., Nathan, P., Bataille, V. A., & Spector, T. D. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01467-x · Cited by 151 · see citing works

Tumor Plasticity and Resistance to Immunotherapy

Horn, L. A., Fousek, K., & Palena, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.001 · Cited by 142 · see citing works

Intracellular and extracellular TGF-β signaling in cancer: some recent topics

Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 141 · see citing works

Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β

Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139 · see citing works

Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting

Heng, W. S., Gosens, R., & Kruyt, F. A. E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.010 · Cited by 138 · see citing works

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 140 · see citing works

Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy

Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129 · see citing works

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 130 · see citing works

CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?

Zhang, C., Fei, Y., Wang, H., Hu, S., Liu, C., Hu, R., & Du, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1113378 · Cited by 129 · see citing works

Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages

Li, Y., Cao, F., Li, M., Li, P., Yu, Y., Xiang, L., Xu, T., Lei, J., Tai, Y., Zhu, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0938-5 · Cited by 125 · see citing works

Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment

Xiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 120 · see citing works

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy

Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 118 · see citing works

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116 · see citing works

A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma

Liu, H., & Weng, J. (2022) · Gene · doi:10.1016/j.gene.2022.146325 · Cited by 115 · see citing works

MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy

Owyong, M., Chou, J., van den Bijgaart, R. J. E., Kong, N., Efe, G., Maynard, C., Talmi-Frank, D., Solomonov, I., Koopman, C. D., Hadler‐Olsen, E., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800226 · Cited by 112 · see citing works

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 115 · see citing works

Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment

Zhou, B., Wu, Q., Wang, M., Hoover, A. R., Wang, X., Zhou, F., Towner, R. A., Smith, N., Saunders, D., Song, J., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.125239 · Cited by 110 · see citing works

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance

Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 111 · see citing works

Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

Wang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 113 · see citing works

Recent developments with immunotherapy for hepatocellular carcinoma

Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 103 · see citing works

The pre-metastatic niche in lymph nodes: formation and characteristics

Gillot, L., Baudin, L., Rouaud, L., Kridelka, F., & Noël, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03873-z · Cited by 105 · see citing works

Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs

Buzdin, A. A., Sorokin, M., Garazha, A., Sekacheva, M. I., Kim, E. L., Zhukov, N. V., Wang, Y., Li, X., Kar, S., Hartmann, C. J., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.003 · Cited by 102 · see citing works

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 104 · see citing works

Quantum computing for near-term applications in generative chemistry and drug discovery.

Pyrkov, A., Aliper, A., Bezrukov, D., Lin, Y.-C., Polykovskiy, D., Kamya, P., Ren, F., & Zhavoronkov, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103675 · Cited by 100 · see citing works

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 98 · see citing works

The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy

Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 102 · see citing works

Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment

Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 96 · see citing works

MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification

Liu, H., & Tang, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-45774-0 · Cited by 94 · see citing works

The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?

Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 97 · see citing works

Product review: Avelumab, an anti-PD-L1 antibody

Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines &amp; Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91 · see citing works

TGF-β signaling networks in the tumor microenvironment

Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90 · see citing works

Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence

Aliper, A., Kudrin, R., Polykovskiy, D. A., Kamya, P. R. N., Tutubalina, E. V., Chen, S., Ren, F., & Zhavoronkov, A. A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3008 · Cited by 106 · see citing works

Expression and potential immune involvement of cuproptosis in kidney renal clear cell carcinoma

Liu, H. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.03.002 · Cited by 86 · see citing works

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

Chia, Z. J., Cao, Y.-N., Little, P. J., & Kamato, D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01235-6 · Cited by 92 · see citing works

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 92 · see citing works

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81 · see citing works

Effects of Radiation on the Tumor Microenvironment

Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 81 · see citing works

Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy

Chen, J., Ding, Z., Li, S., Liu, S., Xiao, C., Li, Z., Zhang, B., Chen, X., & Yang, X. (2020) · Theranostics · doi:10.7150/thno.51383 · Cited by 73 · see citing works

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 75 · see citing works

Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

Malenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 72 · see citing works

The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors

Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 72 · see citing works

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer

Roane, B. M., Arend, R. C., & Birrer, M. J. (2019) · Cancers · doi:10.3390/cancers11050668 · Cited by 69 · see citing works

Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses

Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 68 · see citing works

Crosstalk between macrophages and natural killer cells in the tumor microenvironment

Zhou, J., Zhang, S., & Guo, C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108374 · Cited by 69 · see citing works

Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy

Chen, X., Yang, S., Li, S., Qu, Y., Wang, H.-Y., Liu, J., Dunn, Z. S., Cinay, G. E., MacMullan, M. A., Hu, F., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.014 · Cited by 67 · see citing works

Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy

Guo, M., Liu, M. Y. R., & Brooks, D. G. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.02.005 · Cited by 66 · see citing works

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Yang, Y., Ye, W.-L., Zhang, R., He, X., Wang, J., Liu, Y., Wang, Y., Yang, X., Zhang, Y., & Gan, W.-J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6675208 · Cited by 66 · see citing works

Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy

Liu, Z., Zhong, J., Zeng, J., Duan, X., Lü, J., Sun, X., Liu, Q., Liang, Y., Lin, Z., Zhong, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.735170 · Cited by 61 · see citing works

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1

Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 63 · see citing works

Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

Lian, G., Mak, T. S., Yu, X., & Lan, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010164 · Cited by 63 · see citing works

Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1

Chen, T.-W., Hung, W.-Z., Chiang, S., Chen, W. T., Ke, T., Liang, J., Huang, C.-Y., Yang, P.-C., Huang, K. C., & Chao, K. S. C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215795 · Cited by 59 · see citing works

Drivers of dynamic intratumor heterogeneity and phenotypic plasticity

Biswas, A., & De, S. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00575.2020 · Cited by 59 · see citing works

Algorithmic Annotation of Functional Roles for Components of 3,044 Human Molecular Pathways

Sorokin, M., Borisov, N. M., Kuzmin, D., Gudkov, A., Zolotovskaia, M., Garazha, A., & Buzdin, A. A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.617059 · Cited by 58 · see citing works

Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease

Lemaitre, L., Adeniji, N., Suresh, A., Reguram, R., Zhang, J., Park, J., Reddy, A., Trevino, A. E., Mayer, A. T., Deutzmann, A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00828-8 · Cited by 58 · see citing works

Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment

Stuelten, C. H., & Zhang, Y. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764727 · Cited by 57 · see citing works

Emerging Strategies in TCR-Engineered T Cells

Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 57 · see citing works

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer

Ren, Q., Zhu, P., Zhang, H., Ye, T., Liu, D., Gong, Z., & Xia, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01173-3 · Cited by 53 · see citing works

Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies

Vitale, C., Marzagalli, M., Scaglione, S., Dondero, A., Bottino, C., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14041013 · Cited by 54 · see citing works

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95 · see citing works

Destabilization of intratumor Tregs by CTLA-4 engagement confers anti-CTLA-4-driven immunotherapyPreprint

Liu, N., Xu, J., Ku, W. L., Chen, W., Cao, Y., Kazmi, R., Jin, W., Gauthier, T., Luo, S., Shen, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741328

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

1072 A novel bi-functional antibody fusion protein for the inhibition of TGFβ pathway in cancer immunotherapy via selective delivery of TGFβ ‘trap’ to CD39-expressing cells

Sun, D., Lu, H., Qiu, Q., Niu, X., Sun, J., & Lu, H. (2024) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2024-sitc2024.1072

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · see citing works